版本:
中国

BRIEF-Agile Therapeutics announces results of its pre-submission meeting with FDA

April 11 Agile Therapeutics Inc

* Agile Therapeutics announces results of its pre-submission meeting with FDA

* Agile Therapeutics Inc- It has received final meeting minutes from its recent new drug application

* Agile Therapeutics Inc - FDA indicated that based on preliminary information provided by company, secure trial results appear acceptable for resubmission

* Agile Therapeutics - Has necessary information to complete resubmission of NDA, which is expected to be submitted by end of Q2 of 2017 for Twirla

* Agile Therapeutics - FDA did not provide feedback on if results of secure trial and contents resubmitted NDA will be sufficient for approval of Twirla Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐